A TURBT allows examination beyond the bladder. Complete transurethral resection of bladder tumor prior to neoadjuvant chemotherapy in patients scheduled to undergo radical cystectomy for ...
In a trial of low-grade Ta bladder cancer, photocoagulation was noninferior to standard TURBT in maintaining recurrence-free survival. Office-based laser photocoagulation provides 12-month ...
EORTC GUCG 2418 - STARBURST: Strategies for treatment adaptation following re-evaluation of the bladder after using primary neoadjuvant systemic therapies—An EORTC platform trial. This is an ASCO ...
Secondary analysis of PURE-01: Role of FDG-PET/CT in evaluating lymph node involvement of patients with muscle invasive bladder cancer (MIBC) receiving neoadjuvant pembrolizumab and radical cystectomy ...
The BladderPath study showed mpMRI reduced TTCT by 45 days for MIBC patients, enhancing treatment efficiency without harming non-MIBC patients. Conducted in 17 UK hospitals, the study involved 143 ...
UGN-102 showed high complete response rates in both ENVISION and ATLAS trials for low-grade, intermediate-risk NMIBC. Dysuria was the most common side effect of UGN-102, with other side effects ...
Investors will have to wait for durability of response (DoR) data from Urogen Pharma Ltd.’s phase III Envision study with UGN-102 (mitomycin intravesical solution) in low-grade, intermediate-risk, non ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results